Medical supply distribution has quietly become one of the most searched-on categories in lower-middle-market M&A. Recurring hospital and physician-group contracts, aging ownership, and a long tail of specialty niches that the strategics skip over — it is the kind of category a disciplined searcher can acquire on reasonable terms and grow without needing a breakthrough. But "medical supply" is a catch-all that covers surgical distribution, DME, wound care, home infusion, dental, urology, ostomy, and a dozen adjacent verticals, each with its own reimbursement dynamics and buyer pool. This guide walks through how searchers, ETA investors, and independent sponsors should think about an acquisition of a medical supply company in 2026 — from sourcing to diligence to the first 100 days after close.

TL;DR

Medical supply companies are a strong searcher target: recurring B2B revenue, fragmented ownership, retiring founders, and valuations in the 4x–7x EBITDA range for lower-middle-market deals. The best targets have diversified customers, specialty product lines, low reimbursement exposure, and a founder willing to stay through transition. Finance with SBA 7(a) or conventional senior debt plus seller financing and investor equity. Win the first year on customer retention, not strategic moves.

Why Medical Supply Companies Are a Magnet for Searchers

Medical supply fits the classic search-thesis checklist in ways few other industries do. The category has been quietly rolled up at the top — Medline, Cardinal, Owens & Minor, Henry Schein — but under those giants sits a long tail of regional, specialty, and niche distributors whose revenue is too small for the strategics to chase and too complex for a generalist PE firm to underwrite without operational expertise. That leaves a meaningful acquisition lane for operator-led buyers.

The flip side: medical supply is not a "sleepy" category. Reimbursement, group purchasing organizations, and the consolidation pace of the top four distributors all apply constant pressure on gross margins. A searcher who does not understand that dynamic will overpay for revenue that is structurally melting. For broader context on the distribution landscape, see our overview of the medical supply ecommerce landscape.

Which Medical Supply Niches Are Best for a Searcher

Not every corner of medical supply suits a first-time operator. Three variables separate the attractive niches from the traps: reimbursement exposure, customer type, and product specialization.

Good fit: specialty distribution into surgery centers and IDNs

Surgical, orthopedic, urology, wound care, and ophthalmic distribution into ambulatory surgery centers, office-based labs, and integrated delivery networks are the sweet spot. Contracts are direct to the facility, margins are protected by clinical specificity, and reimbursement risk sits with the provider rather than the distributor. A searcher with sales-operations chops can grow these businesses meaningfully.

Good fit: B2B procedural and practice supply

Dental, veterinary, dermatology, and plastic surgery practice supply — clinic-facing distribution with repeat ordering and low regulatory complexity — is consistently attractive. These businesses rarely have direct Medicare exposure and grow through sales-rep productivity rather than reimbursement lobbying.

Caution: DME and home infusion

Durable medical equipment and home infusion businesses can generate strong cash flow but sit directly in the path of Medicare and Medicare Advantage reimbursement cycles. CMS competitive bidding rounds, local coverage determinations, and payer formulary changes can compress margin by hundreds of basis points in a single quarter. Searchable but only with deep reimbursement expertise or an operating partner already in the space.

Avoid as a first acquisition: commodity general supply

Commodity gloves, gauze, wipes, and PPE distribution compete directly against Medline and Cardinal on price. Gross margins are structurally thin, private-label pressure is intense, and the buyer universe has moved to GPO contracts that favor scale. This is a scale game, not a niche game, and not where a searcher wins.

How to Source Medical Supply Acquisition Targets

Searchers chasing medical supply deals typically run a four-channel sourcing strategy. The best deal flow comes from direct outreach, not listings.

  1. Direct owner outreach. Build a list of 500–1,500 companies matching your size, geography, and niche criteria using a combination of D&B Hoovers, ZoomInfo, HIDA's membership directory, and state medical supply association rosters. Run multi-touch email and direct mail against every owner for 12–24 months. Most closed searcher deals come from cold outreach into that list.
  2. Healthcare-focused lower-middle-market brokers. A handful of banks and advisors specialize in this space — Stax, Provident, Capstone Partners, and a dozen smaller boutiques. Get on every relevant buyer list and respond fast when a CIM lands.
  3. Industry conferences and associations. HIDA Executive Conference, Medtrade, AAOS, and specialty trade shows are prime relationship venues. Walk the distributor aisles, not just the booths.
  4. Peer referrals from operators and professional services. Accountants, lawyers, and wealth managers in the target geography often know three or four local owners who have been quietly exploring exits. Build those relationships early.

Most searchers underestimate how long sourcing takes. Plan on 18–30 months from search launch to close. The right deal almost never appears when you expect it to.

Acquiring a medical supply company? Let's pressure-test your growth plan.

Free 30-minute strategy call. We'll review your target's marketing, sales, and digital footprint — and tell you exactly what we'd fix in year one.

Book a Free Strategy Call →

Valuation: What a Medical Supply Company Is Worth in 2026

Lower-middle-market medical supply deals in 2026 are transacting at 4x to 7x adjusted EBITDA. The wider the range, the more variables explain it.

Premium drivers: proprietary or private-label SKUs, direct contracts with IDNs or national GPOs (not just subcontracts), recurring auto-ship revenue, management team depth beyond the founder, and clean quality systems for FDA-regulated product handling. Discount drivers: customer concentration above 25%, gross-margin decline, Medicare reimbursement exposure, dependent relationships with a single manufacturer, and an owner whose departure creates real customer or vendor risk.

Adjusted EBITDA matters more than top-line in this category. Expect heavy normalization work on owner compensation, family members on payroll, personal expenses, and inventory reserve accuracy. On more than one deal we have seen reported EBITDA shrink 15–20% once a quality-of-earnings team finishes. Build that haircut into your LOI.

Diligence: The Risks That Kill Medical Supply Deals

Financial diligence catches the numbers. Commercial, regulatory, and operational diligence catch the deal-killers.

Customer concentration and contract portability

Pull a customer-level revenue waterfall for the last five years. Flag every account above 10% of revenue. For each, confirm the contract is with the company entity — not the owner personally, not a handshake — and that it survives a change of control. In-person reference calls with the top five customers before close are worth the risk of tipping the deal.

Reimbursement and payer mix

Understand exactly how much of the revenue touches Medicare, Medicaid, Medicare Advantage, or commercial insurance billing — directly or indirectly. For DME, home infusion, and orthotic supply, request the last three years of competitive-bidding and LCD change impact analyses. A 10% reimbursement cut can swing EBITDA by 30% or more.

Inventory quality and consignment reconciliation

Walk the warehouse. Look at expiration-dated SKUs, sit with the inventory controller, and reconcile physical count to book value. If the target runs consignment inventory at hospitals or surgery centers, the risk multiplies: consigned inventory is frequently overstated on the books, misplaced, or held past the expiration window. Bring in a third party to do a physical count if consignment is more than 15% of inventory.

Vendor and manufacturer agreements

Many distributor agreements include change-of-control clauses. The target's exclusive distribution rights for a key product line may terminate on close unless renegotiated in advance. Map every material vendor agreement and get written consent to the transaction before you fund.

Quality, regulatory, and recalls

For FDA-registered establishments — and many medical supply distributors are — pull the FDA inspection history, any 483s or warning letters, and confirm Establishment Registration and Device Listing are current. See our deep dive on FDA marketing compliance and the related regulatory considerations a new owner inherits.

Financing the Acquisition

A lower-middle-market medical supply deal almost never uses a single capital source. The common stack for a self-funded searcher or ETA investor looks like this.

SBA 7(a) is powerful for searchers because of its 10-year amortization, low equity requirement (as low as 10%), and personal-guarantee structure. The trade-off is the personal guarantee itself — be honest with yourself about what you are willing to sign.

The First 100 Days After Close

Searchers consistently underperform in year one not because they made bad strategic choices but because they made strategic choices at all. The first 100 days belong to stabilization.

  1. Meet the top 20 customers in person within 60 days. Bring the founder if available. The goal is relationship transfer, not selling.
  2. Reconfirm key vendor and manufacturer agreements. Written confirmation of ongoing distribution rights, pricing, and terms — not verbal.
  3. Stabilize the team. Identify the three to five people without whom the company cannot operate. Talk to each of them personally in the first two weeks. Retention is about signal more than money in the first 30 days.
  4. Install financial visibility. Basic weekly cash, AR, inventory, and sales reporting. You cannot manage what you cannot see, and sub-$10M medical supply companies almost never have it.
  5. Freeze major changes. Pricing, ERP, branding, sales-comp, and territory moves can wait until quarter two at the earliest. Changing too much too fast is the number-one failure pattern in post-close supply-distribution integrations.

By month four, you should have a 12-month operating plan: customer retention KPIs, sales productivity targets, gross-margin initiatives, and one or two strategic growth bets. Not before.

Where Growth Actually Comes From

After stabilization, most medical supply companies have three to five latent growth levers that a new operator can unlock in 18–36 months.

None of these levers require breakthrough innovation. They require a disciplined operator who shows up every day for three to five years.

The Bottom Line

Medical supply distribution is one of the most operator-friendly acquisition categories available to a searcher in 2026. The math is attractive because recurring B2B revenue, aging ownership, and industry fragmentation haven't yet been priced out of the lower middle market. The wins come to searchers who pick a defensible niche, pay a disciplined multiple, finance with a balanced stack, and spend year one on customer retention before they touch the strategy deck. Skip the reimbursement-heavy corners until you have operator experience, and build the marketing and sales infrastructure most sellers never bothered to put in place. That is where the real returns hide.